• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.930 -0.060 (-3.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
July 13, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
July 10, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
July 07, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
June 29, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
June 22, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
June 18, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
June 16, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
June 05, 2026
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar 
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare
June 03, 2026
Via AB Newswire
Topics Artificial Intelligence Energy Intellectual Property
News headline image
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
May 29, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
May 26, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces 1-for-10 Reverse Share Split
May 19, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
May 18, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
May 15, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
May 12, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
May 11, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
May 05, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
April 27, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Kartoon Studios (NYSE: TOON) Gaining Momentum Alongside CMND, ENVB, WLDS, ANY – See Why?
April 20, 2026
Via AB Newswire
Topics Intellectual Property
News headline image
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
April 20, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
April 20, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
April 15, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
April 14, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
March 30, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
March 27, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
March 19, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
March 17, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
March 11, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 10, 2026
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap